hackint0sh/New-Dataset huggingface dataset:
* Third: control phase with measurement of the maximum grip force every ten minutes without vibration. conditions: Stroke conditions: Stroke, Acute conditions: Fatigue studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 50 type: ESTIMATED name: Vibration measure: Maximum handgrip strength measured by a digital dynamometer measure: Fatigue evolution measure: Evolution of handgrip strength during the vibration session measured by a digital dynamometer sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CH de Chartres status: NOT_YET_RECRUITING city: Chartres country: France name: Valentin BOHOTIN, Dr role: CONTACT email: vbohotin@ch-chartres.fr name: Valentin BOHOTIN, Dr role: PRINCIPAL_INVESTIGATOR lat: 48.44685 lon: 1.48925 facility: CHU d'ORLEANS status: RECRUITING city: Orleans zip: 45067 country: France name: Canan OZSANCAK, Ph role: CONTACT email: canan.ozsancak@chu-orleans.fr name: Andreea AIGNATOAIE, Ph role: PRINCIPAL_INVESTIGATOR lat: 47.90289 lon: 1.90389 facility: Hopital Pitie Salpetriere status: NOT_YET_RECRUITING city: Paris country: France name: Charlotte ROSSO, Pr role: CONTACT email: charlotte.rosso@aphp.fr name: Charlotte ROSSO, Pr role: PRINCIPAL_INVESTIGATOR lat: 48.85341 lon: 2.3488 facility: CHU de Tours status: NOT_YET_RECRUITING city: Tours country: France name: Marco PASI, Dr role: CONTACT email: m.pasi@chu-tours.fr name: Marco PASI, Dr role: PRINCIPAL_INVESTIGATOR lat: 47.38333 lon: 0.68333 hasResults: False
nctId: NCT06296212 id: GLT-07-22 briefTitle: Study of Intravenous TAD® 600 mg/4 mL Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients With Pneumonia. overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2024-09-30 date: 2025-09-30 date: 2024-03-06 date: 2024-03-06 name: Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica class: INDUSTRY briefSummary: The goal of this PHASE III clinical trial is to evaluate efficacy and safety of intravenous TAD® 600 mg/4 mL solution for injection in preventing myocardial injury in patients with pneumonia.
* patients will then be required to undergo five Follow-up Visits. conditions: Pneumonia conditions: Myocardial Injury studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 178 type: ESTIMATED name: TAD® 600 mg/4 mL powder and solvent for solution for injection name: Saline solution 0.9% of sodium chloride measure: Assessment of the change of levels of high-sensitivity cardiac Troponin (hs-cTn) at V1 versus V0 in the two groups. sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Azienda Ospedaliero-Universitaria Pisana city: Pisa state: PI zip: 56126 country: Italy name: Massimiliano Desideri role: CONTACT lat: 43.70853 lon: 10.4036 facility: Fondazione Policlinico Universitario Campus Bio-Medico city: Roma state: RM zip: 00128 country: Italy name: Francesco Grigioni role: CONTACT lat: 41.89193 lon: 12.51133 facility: Azienda Ospedaliera Universitaria Policlinico Tor Vergata city: Roma state: RM zip: 00133 country: Italy name: Francesco Barillà role: CONTACT lat: 41.89193 lon: 12.51133 facility: Azienda Ospedaliero-Universitaria Policlinico Umberto I city: Roma state: RM zip: 00161 country: Italy name: Pasquale Pignatelli role: CONTACT lat: 41.89193 lon: 12.51133 facility: Azienda Ospedaliero-Universitaria Sant'Andrea city: Roma state: RM zip: 00189 country: Italy name: Alberto Ricci role: CONTACT lat: 41.89193 lon: 12.51133 facility: Azienda Ospedaliera Santa Maria city: Terni state: TR zip: 05100 country: Italy name: Giacomo Pucci role: CONTACT lat: 42.56335 lon: 12.64329 facility: Ospedale Ca' Foncello city: Treviso state: TV zip: 31100 country: Italy name: Marcello Rattazzi role: CONTACT lat: 45.66673 lon: 12.2416 hasResults: False
nctId: NCT06296199 id: 2024-2064 briefTitle: Music, Virtual Reality for Inpatients in IUGM overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-12 date: 2025-05 date: 2024-03-06 date: 2024-03-06 name: Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal class: OTHER_GOV briefSummary: Promoting good care, well-being and quality of life for geriatric patients is a long-standing initiative in Quebec, and one in which the Institut Universitaire de Gériatrie de Montréal (IUGM) has always been a leader. For example, the IUGM played a major role in drafting the reference framework for the AAPA (approach adapted to the needs of the elderly), which was introduced by the Ministère de la Santé et des Services Sociaux in 2011. The investigator propose to continue this work by focusing in this project on the development of a new intervention aimed at the well-being and quality of life of geriatric patients and based on music and VR.
Thee investigator hypothesize (1) that a VR headset-based intervention based on listening to and observing a concert of musicians playing classical music is feasible for patients hospitalized at the IUGM's URFI, and (2) that this intervention can improve their mental health - i.e. their positive emotions, well-being and quality of life - and reduce their anxiety. conditions: Aging conditions: Disorder, Neurologic studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 40 type: ESTIMATED name: VR name: Music only measure: Feasability measure: Emotions variation measure: Affect variation measure: Well-Being Variation measure: Quality of life variation measure: Anxiety variation sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06296186 id: HT94252310669 briefTitle: Massed Prolonged Exposure for PTSD in Substance Use Treatment acronym: PREVAIL overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-07 date: 2027-08 date: 2024-03-06 date: 2024-03-06 name: Veterans Medical Research Foundation class: OTHER name: University of Minnesota name: Center for Veterans Research and Education briefSummary: The goal of this clinical trial is to learn if receiving Prolonged Exposure Therapy for PTSD in massed format (multiple sessions weekly) is as effective as receiving it with sessions once per week among veterans with PTSD and substance use disorder in intensive outpatient substance use treatment. The main questions it aims to answer are:
* Will it help participants reduce substance use? Participants who are in intensive substance use treatment will be asked to complete Prolonged Exposure with either weekly sessions or multiple sessions per week. conditions: Stress Disorders, Post-Traumatic conditions: Substance Use Disorders studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 200 type: ESTIMATED name: Prolonged Exposure Therapy measure: Clinician Administered PTSD Scale for DSM-5 (CAPS-5) measure: Time Line Follow back (TLFB) measure: Psychotherapy Completion Rates measure: Patient Health Questionnaire-9 (PHQ-9) measure: Brief Psychosocial Functioning Inventory (B-IPF) measure: Client Satisfaction Questionnaire-8 (CSQ-8) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: VA San Diego Healthcare System city: San Diego state: California zip: 92161 country: United States name: Sonya Norman, PhD role: CONTACT phone: 858-518-8266 email: sonya.norman@va.gov lat: 32.71533 lon: -117.15726 facility: VA Tampa Healthcare System city: Tampa state: Florida zip: 33612 country: United States name: Brittany Davis, PhD role: CONTACT phone: 813-972-2000 email: brittany.davis@va.gov lat: 27.94752 lon: -82.45843 facility: VA Atlanta Healthcare System city: Atlanta state: Georgia zip: 30033 country: United States name: Kristin Lamp, PhD role: CONTACT email: kristen.lamp@va.gov lat: 33.749 lon: -84.38798 facility: Hines VA Healthcare System city: Chicago state: Illinois zip: 60141 country: United States name: Jonathan Bayer, PhD role: CONTACT email: jonathan.bayer2@va.gov lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06296173 id: MP-02-2024-12094 briefTitle: Open Lung Protective Extubation Following General Anesthesia acronym: OLEXT-3 overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2025-12-01 date: 2026-04-01 date: 2024-03-06 date: 2024-03-06 name: Centre hospitalier de l'Université de Montréal (CHUM) class: OTHER name: CHU de Quebec-Universite Laval name: The Ottawa Hospital name: University Health Network, Toronto name: Canadian Institutes of Health Research (CIHR) briefSummary: Perioperative respiratory complications are a major source of morbidity and mortality. Postoperative atelectasis plays a central role in their development. Protective "open lung" mechanical ventilation aims to minimize the occurrence of atelectasis during the perioperative period. Randomized controlled studies have been performed comparing various "open lung" ventilation protocols, but these studies report varying and conflicting effects. The interpretation of these studies is complicated by the absence of imagery supporting the pulmonary impact associated with the use of different ventilation strategies. Imaging studies suggest that the gain in pulmonary gas content in "open lung" ventilation regimens disappears within minutes after the extubation. Thus, the potential benefits of open-lung ventilation appear to be lost if, at the time of extubation, no measures are used to keep the lungs well aerated. Recent expert recommendations on good mechanical ventilation practices in the operating room conclude that there is actually no quality study on extubation.
nctId: NCT06296160 id: MRC-01-23-035 id: LUSAM-HD type: OTHER_GRANT domain: COMITE D'ETHIQUE du CHU BRUGMANN c/o Direction Médicale briefTitle: A Simplified Lung Ultrasound Guided Management Protocol Of Pulmonary Congestion in Hemodialysis overallStatus: RECRUITING date: 2023-05-28 date: 2024-05-22 date: 2024-05-22 date: 2024-03-06 date: 2024-03-06 name: Hamad Medical Corporation class: INDUSTRY name: Brugmann University Hospital briefSummary: Pulmonary congestion secondary to volume overload or interstitial tissue inflammation is common in chronic hemodialysis patients. This pulmonary congestion occurs mainly during the period between dialysis sessions and is an independent risk factor for cardiovascular event morbidity and mortality in this population. The evaluation of this pulmonary congestion and the estimation of the dry weight of hemodialysis patients according to conventional methods represent a real challenge for clinical nephrologists. Lung ultrasound is a new diagnostic approach validated in the assessment of pulmonary congestion. It would allow a better assessment of dry weight in chronic hemodialysis patients based on the results of preliminary studies, including our latest pilot study. However, there is little evidence comparing this novel approach to traditional approaches. conditions: End Stage Renal Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study will compare two groups according to the dry weight determination method:
(1) Control arm- modification of dry weight according to standardized care only. The standard of care to modify dry weight is what nephrologists use actually to define the best theoretical dry weight, including clinical (blood pressure, edema, shortness of breath, lung auscultation, etc.) and laboratory measures (Protein concentration before and after dialysis sessions ...). (2) Intervention arm- modify patient's dry weight according to standard of care + B lines score on lung ultrasound BLS obtained after the midweek dialysis session, considered as Day one (Day 1) primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE maskingDescription: It is a single-blinded trial as the treatment is blinded by Subjects only, meaning that the type of dry weight modification will not be disclosed to the subject, and they will not know which group he/she will be in at the time of consenting to limit the bias in opinion. The investigator and the research team must know the type of treatment, as the investigator will modify the dry weight according to the treatment group. whoMasked: PARTICIPANT count: 100 type: ESTIMATED name: Intervention Group measure: Assess the effectiveness of adding B-line score evaluation through lung ultrasound to the standard of care to improve pulmonary congestion (measured by B lines score) in hemodialysis patients measure: The impact of utilizing B lines score based additional fluid removal on interdialytic ambulatory blood pressure. measure: The impact of utilizing B lines score based additional fluid removal on intradialytic ambulatory blood pressure sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kaysi Saleh status: RECRUITING city: Bruxelles state: Van Gehuchten zip: 1020 country: Belgium name: Nortier Joelle, PHD role: CONTACT phone: +33643250634 email: saleh.kaysi@chu-brugmann.be lat: 50.85045 lon: 4.34878 hasResults: False
nctId: NCT06296147 id: STUDY23080006 briefTitle: Virtual Reality Headset and/or Aromatherapy for Patients Undergoing a Transperineal Prostate Biopsy overallStatus: RECRUITING date: 2024-03-10 date: 2024-11-01 date: 2024-11-01 date: 2024-03-06 date: 2024-03-06 name: University of Pittsburgh class: OTHER briefSummary: The purpose of this study is to evaluate if a VR headset and/or aromatherapy can be used to reduce patient pain, anxiety, and embarrassment during a transperineal biopsy (TPBx) compared to standard of care (SOC). The primary objective is to evaluate differences in self-reported pain, fear, or embarrassment during and after the procedure between the VR Group, Aromatherapy Group, VR+Aromatherapy Group, and the Control group. conditions: Prostate Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 208 type: ESTIMATED name: Virtual Reality Headset name: Aromatherapy Patch name: Standard of Care measure: Levels of pain, fear, and embarrassment that each group experienced before the TPBx measured using a self-reported survey that asks about experience prior to biopsy. The survey will be provided after the procedure. measure: Levels of pain, fear, and embarrassment that each group experienced during the TPBx measured using a self-reported survey that asks about experience during the biopsy. The survey will be provided after the procedure. measure: Levels of pain, fear, and embarrassment that each group experienced after the TPBx measured using a self-reported survey that asks about experience after to biopsy. The survey will be provided after the procedure. measure: Proportion of patients undergoing TPBx who would be interested in using a VR device or aromatherapy patch during the procedure. measure: Safety and feasibility of using a VR device or aromatherapy patch during TPBx via the proportion of procedures completed successfully with no major complications or prolongations. sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Pittsburgh Medical Center Shadyside Hospital status: RECRUITING city: Pittsburgh state: Pennsylvania zip: 15232 country: United States name: Divya Natesan, BS role: CONTACT email: din15@pitt.edu name: John Myrga, MD role: CONTACT email: myrgajm@upmc.edu name: Bruce Jacobs, MD role: PRINCIPAL_INVESTIGATOR lat: 40.44062 lon: -79.99589 hasResults: False
nctId: NCT06296134 id: 17501 briefTitle: Perineal Massage in Pregnancy to Reduce the Levator Ani Coactivation acronym: CO-LAM23 overallStatus: NOT_YET_RECRUITING date: 2024-03-11 date: 2024-12-31 date: 2025-12-31 date: 2024-03-06 date: 2024-03-06 name: Azienda Sanitaria Universitaria Friuli Centrale class: OTHER briefSummary: The goal of this clinical trial is to test the efficacy of the perineal massage in reducing the levator ani muscle (LAM) co-activation. This phenomenon is characterized by the LAM contraction rather than its relaxation during the Valsalva maneuver and it is associated with adverse obstetric outcome. Participants who co-activate will be enrolled and randomized in 2 groups: group A, where women themselves perform the perineal massage during the third trimester of pregnancy and group B, where women undergo the standard care. Researchers will compare these groups to see if the perineal massage is able to reduce LAM co-activation. conditions: Pelvic Floor Disorders conditions: Levator Ani Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 58 type: ESTIMATED name: perineal massage measure: Comparison of the percentages of women without levator ani muscle co-activation after treatment or after standard care, evaluated at 37-38 weeks of gestation, using chi square test. measure: Evaluation of significant differences in spontaneous or iatrogenic vaginal tears between the groups measure: percentage of women who completely adhere to perineal massage, i.e. who perform the perineal massage once a day, at least 5 days a week, from 34 gestational weeks until delivery. sex: FEMALE minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Serena Xodo city: Udine zip: 33100 country: Italy name: Serena Xodo role: CONTACT phone: 0432-559699 email: serena.xodo@gmail.com lat: 46.0693 lon: 13.23715 hasResults: False
nctId: NCT06296108 id: I05-310-22 briefTitle: Risk Factors for Acute Kidney Injury in Patients Undergoing Arthroplasty overallStatus: COMPLETED date: 2022-06-01 date: 2022-12-31 date: 2022-12-31 date: 2024-03-06 date: 2024-03-06 name: Ankara University class: OTHER briefSummary: The authors aimed to determine the risk factors associated with postoperative acute kidney injury in patients undergoing total joint arthroplasty. conditions: Postoperative Acute Kidney Injury conditions: Arthroplasty studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 911 type: ACTUAL name: acute kidney injury measure: Acute kidney injury in patients undergoing arthroplasty surgery measure: Risk factors causing acute kidney injury in patients undergoing arthroplasty surgery sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara University Medical School Anesthesiology and ICU Department city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06296095 id: KDS-CUD-1 briefTitle: To Evaluate the Clinical Study of CUD005 Injection in Patients With Cirrhosis overallStatus: ENROLLING_BY_INVITATION date: 2023-08-09 date: 2024-10-31 date: 2024-12-31 date: 2024-03-06 date: 2024-03-06 name: Anhui Provincial Hospital class: OTHER_GOV briefSummary: The study is a single-center, single-arm, open-label, dose-escalation clinical study, to evaluate the tolerability, safety and preliminary efficacy of CUD005 injection in patients with cirrhosis conditions: Cirrhosis, Liver studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 9 type: ESTIMATED name: Cell therapy measure: DLT,MTD measure: fibrosis staging and inflammatory grading measure: All-cause mortality measure: TE（Transient elastography） measure: MELD（Model for End-stage Liver Disease） sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Anhui province hospital city: Hefei state: Anhui zip: 230000 country: China lat: 31.86389 lon: 117.28083 hasResults: False
nctId: NCT06296082 id: 49317 briefTitle: Comparative Study of the Mechanism of Action of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Spasticity: a Proof of Concept Controlled Trial acronym: STROKEPOC overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-03-31 date: 2027-06-30 date: 2024-03-06 date: 2024-03-06 name: Universiteit Antwerpen class: OTHER name: McGill University name: Aragon Institute of Health Sciences briefSummary: Trial design This study is a protocol of a phase II clinical trial which will be conducted in two countries (Belgium and Spain) to compare the effectiveness of DN and BTX A in reducing post-stroke spasticity in the plantar flexor muscles. This study is a prospective randomized, controlled, multiple-baseline design with blinded assessors. The study will be registered in ClinicalTrials.gov and will have a length of 19 weeks
Trial population Inclusion Criteria: 1) aged 18-75 years old, 2) having lower limb post-stroke spasticity in ankle plantar flexors (MAS scores of 1, 1+ and 2); 3) having had a first stroke; 4) having no more than 12 months of evolution since stroke; 5) having no previous Dry Needling (DN) or Botulinum Toxin type A (BTX A) treatment for spasticity; 6) having ankle PROM ≥ 20° (approx.) when the knee is supported in \~30° flexion; 7) being able to walk independently with or without aids.
Exclusion Criteria: 1) medical conditions interfering with data interpretation; 2) any contraindication to receiving BTX A or PS treatment; 3) If taking anti-spasticity medications, participants must be on stable medication for at least 3 months prior to the start of the study and neither the dose nor the medication can be changed during the tria Interventions Participants will be randomly allocated to the group receiving a session of BTX A or to the group receiving Dry Needling once weekly for 12 weeks. Blinded evaluators will assess the effects before, during, after treatment, and at 4-week follow-up.
The trial will have regular monitoring visits by an independent external monitor to ensure compliance with the protocol and Good Clinical Practices. Monitors may review source documents to confirm accurate data on CRD. The investigator and institution will guarantee direct access to source documents for monitors and regulatory authorities. conditions: Stroke conditions: Spasticity as Sequela of Stroke studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomly allocated to the group receiving a session of BTX A or to the group receiving Dry Needling once weekly for 12 weeks. Each group will be assessed equally during the 19 weeks of the study duration. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Participant will be randomized but ultimately will know which treatment he/she receives. A distinct investigator/assessor and intervention therapist wil be selected to treat or assess the participant whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 90 type: ESTIMATED name: Botulinum toxin type A name: Dry Needling measure: tonic stretch reflex threshold measure: Passive Resistance measure: Ultrasound Imaging: Morphometric Analysis measure: Ultrasound Imaging: Eco-textural Analysis of Muscle: measure: Dynamometry measure: Gait Analysis measure: 10 Meter Walk Test (10MWT) measure: Timed up and Go Assessment (TUG) measure: Quality of Life EuroQoL 5D measure: EQ visual analogue scale (EQ VAS) measure: Cost-effectiveness measure: Patient Acceptance measure: Frequency and Severity of Adverse Events for DN and BTX A measure: Sample size measure: Sample size and drop out sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06296069 id: SwingIT-stroke briefTitle: Exergames on an Unstable Surface in Stroke Inpatients overallStatus: RECRUITING date: 2024-02-28 date: 2024-07-31 date: 2024-07-31 date: 2024-03-06 date: 2024-04-17 name: Eleftheria Giannouli class: OTHER briefSummary: Aim of this study is to assess the feasibility and effects of exergame-based cognitive-motor training on a labile platform on physical and cognitive functioning in stroke inpatients.